Artesunate vaginal inserts

DRUG2 trials

Sponsors

UNC Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill Department of Obstetrics and Gynecology

Conditions

CancerCervical PrecancerHuman Immunodeficiency VirusHuman Papillomavirus

Phase 1

IGHID 12333 Study

Active, not recruitingPACTR202402687748210

University of North Carolina Chapel Hill Department of Obstetrics and GynecologyCancer

Start: 2024-04-01Target: 12Updated: 2026-09-14

Phase 2

Feasibility of Intravaginal Artesunate as Adjuvant HPV & Cervical Precancer Treatment in Kenya

CompletedNCT06519994

UNC Lineberger Comprehensive Cancer CenterCervical Precancer, Human Immunodeficiency Virus, Human Papillomavirus

Start: 2025-01-22End: 2026-04-08Updated: 2026-05-14

Related Papers

Feasibility of Intravaginal Artesunate as an Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya: Study Protocol for a Phase II Clinical Trial

UNC Libraries2025-09-09

Feasibility of Intravaginal Artesunate as an Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya: Study Protocol for a Phase II Clinical Trial

Cancer Control2025-08-01